Tumors exploit the neuropeptide CGRP to drive growth, suppress immunity, and remodel their environment — making CGRP a promising new target for cancer therapy.
CGRP-mediated neural addictionTumors become dependent on CGRP signaling from nearby nerves to sustain growth and immune evasion, suggesting that disrupting this 'addiction' could be a new cancer treatment strategy.
What the researchers found
CGRP (calcitonin gene-related peptide) is emerging as a key mediator of tumor-nerve crosstalk that drives cancer growth, suppresses anti-tumor immunity, and contributes to cancer-associated symptoms. The concept of 'CGRP-mediated neural addiction' describes how tumors hijack neural signaling through CGRP to remodel their microenvironment and sustain growth, positioning CGRP as a promising therapeutic target for disrupting tumor-nerve interactions.
Why it matters
While CGRP is well known in migraine treatment, its role in cancer is a rapidly emerging field. This perspective reveals that the same peptide targeted by migraine drugs may be exploited by tumors to grow, evade the immune system, and cause symptoms. Given that anti-CGRP drugs are already widely available and safe, this opens the possibility of repurposing migraine medications for cancer treatment — a paradigm-shifting concept.
The numbers in context
Perspective article · CGRP identified as neural driver of tumor growth, immune suppression, and cancer symptoms · tumor-nerve interaction framework
How the study worked
This is a perspective/commentary article published in Trends in Cancer that synthesizes emerging evidence on CGRP's role in tumor-nerve crosstalk. It presents the conceptual framework of 'CGRP-mediated neural addiction' in cancer biology.
Who was studied
Perspective article — no patient population
What this study cannot tell us
As a short perspective piece, it presents a conceptual framework rather than new experimental data. Much of the evidence for CGRP's role in cancer is still preclinical. The concept of 'neural addiction' in tumors is relatively new and requires further mechanistic validation across multiple cancer types.
How to read the evidence
This is a perspective article synthesizing emerging evidence, not a primary research study. It presents a conceptual framework supported by growing preclinical data but does not provide new experimental evidence.
When this study was published
Published in 2025 in Trends in Cancer, this perspective reflects the cutting edge of neuro-tumor crosstalk research and CGRP biology in oncology.
The bigger picture
The concept of neuro-tumor crosstalk is reshaping cancer biology. CGRP sits at the intersection of two major therapeutic areas — migraine and cancer — with approved anti-CGRP drugs already in widespread clinical use for migraine. If CGRP's pro-tumor effects are confirmed in clinical studies, the existing arsenal of anti-CGRP antibodies (erenumab, fremanezumab, galcanezumab) and small molecule antagonists could be rapidly repurposed for oncology, representing one of the most exciting peptide drug repurposing opportunities in medicine.
Questions still open
- Do migraine patients on anti-CGRP therapy have lower cancer incidence or better cancer outcomes?
- Which cancer types are most dependent on CGRP-mediated neural signaling?
- Could combining anti-CGRP antibodies with checkpoint inhibitors overcome tumor immune suppression more effectively?
Common questions
What is 'neural addiction' in cancer?
Could migraine drugs be used to treat cancer?
Read the original research
CGRP-mediated neural addiction in tumor dynamic remodeling.
Trends in cancer, 11(9), 834-838
Citation
Xu, Miaochun; Yu, Yang; Cao, Canhui. (2025). CGRP-mediated neural addiction in tumor dynamic remodeling.. Trends in cancer, 11(9), 834-838. https://doi.org/10.1016/j.trecan.2025.07.004